HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Ioversol

HCID 3741
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
8771-40-2
Standard SMILES
O=C(NCC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(N(CCO)C(=O)CO)c1I
InChIKey
AMDBBAQNWSUWGN-UHFFFAOYSA-N
Molecular formula
C18H24I3N3O9
Average molar mass
807.1 g/mol
Monoisotopic mass
806.8647

Overview

Ioversol is an amidobenzoic acid.

Names & identifiers

Preferred name
Ioversol
IUPAC
1-N,3-N-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-(2-hydroxyethyl)amino]-2,4,6-triiodobenzene-1,3-dicarboxamide
English name
Ioversol
Molecular formula
C18H24I3N3O9
Molecular weight
807.11

Names & synonyms

ioversol87771-40-2OptirayMP-328Optiray 320IoversolumOptiray 160Optiray 240Optiray 300Optiray 350DTXSID2045521MP 328
Show more names
LoversolP 530oversolIodofolIodophorolIoversol API
1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)(2-hydroxyethyl)amino)-2,4,6-triiodo-N3RIB7X24KN,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2-hydroxyethyl)glycolamido)-2,4,6-triiodoisophthalamideDTXCID0025521N1,N3-bis(2,3-dihydroxypropyl)-5-[2-hydroxy-N-(2-hydroxyethyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamideioversoloN1,N3-bis(2,3-dihydroxypropyl)-5-(2-hydroxy-N-(2-hydroxyethyl)acetamido)-2,4,6-triiodobenzene-1,3-dicarboxamideRefChem:57669

Database identifiers

CAS
8771-40-2、87771-40-2
PubChem CID
3741
DTXSID
DTXSID2045521
ChEMBL
CHEMBL1200614
ChEBI
CHEBI:31717
UNII
N3RIB7X24K
EC Number
618-068-0
Nikkaji
J33.102C

Properties

Computed structural properties

XLogP
-3
Topological polar surface area
200 Ų
Hydrogen bond donors
8
Hydrogen bond acceptors
9
Rotatable bonds
12
Heavy atoms
33
Formal charge
0
Complexity
623

Experimental & physicochemical properties

DrugsPharmaceuticals
LogP-2.98
SolubilityWater soluble
Human Drugs · 3 items

Breast Feeding; Lactation; Milk, Human; Contrast Media; Diagnostic Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point180-182°C
Collision Cross Section216.25 Ų [M+H]+

Physicochemical properties

Melting point
180 · 180-182°C
Boiling point
864.9 · 864.9±65.0 °C(Predicted)
Density
37 · d37 1.371 (c = 320 mgI/ml)
storage temp.
Refrigerator
solubility
DMSO (Sparingly), Methanol (Slightly)
pka
11.34 · 11.34±0.46(Predicted)
form
Solid
color
White to Off-White
Major Application
pharmaceutical
InChI
InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33)
InChIKey
AMDBBAQNWSUWGN-UHFFFAOYSA-N
SMILES
C1(C(NCC(O)CO)=O)=C(I)C(N(C(CO)=O)CCO)=C(I)C(C(NCC(O)CO)=O)=C1I
CAS DataBase Reference
87771 · 87771-40-2(CAS DataBase Reference)
FDA UNII
3 RIB7X24K · N3RIB7X24K
NCI Drug Dictionary
Ioversol
ATC code
8 AB07 · V08AB07
Comptox DTXSID
2045521 · DTXSID2045521
UNSPSC Code
41116107 · 41116107
NACRES
21 · NA.21
WGK Germany
3 · WGK 3
HS Code
2924296000 · 2924296000
Storage Class
11 · 11 - Combustible Solids
Toxicity
50 in · LD50 in mice, rats, rabbits, dogs (gI/kg): 17, 15, >25, >12 i.v.; in male, female rats (mgI/kg): 1000, >1200 intracisternally (Ralston)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Toxicology

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Ioversol

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

wgk
WGK 3
hs_code
2924296000
Toxicity
LD50 in mice, rats, rabbits, dogs (gI/kg): 17, 15, >25, >12 i.v.; in male, female rats (mgI/kg): 1000, >1200 intracisternally (Ralston)
Storage Class
11 - Combustible Solids

Chemistry & industry

Pharmacology

ATC Code · 3 items

V08AB07

V - Various

QV - Various

Protein BindingIoversol does not bind to serum or plasma proteins.
Pharmacodynamics · 1 item

The contrast enhancement obtained with ioversol is related to iodine content. Immediately after ioversol is injected, a peak in iodine plasma levels can be detected. However, depending on the organ being imaged, the time to maximum contrast will vary. The time to maximum contrast enhancement will range from the time iodine plasma levels reach their highest concentration to one hour after intravenous bolus administration. The delay between a peak in iodine plasma levels and maximum contrast enhancement is partly due to the accumulation of iodine-containing medium within a lesion and outside the blood pool. For angiographies, the maximum contrast enhancement of ioversol occurs almost immediately (15-120 seconds). Following rapid intravenous injection, ioversol can be visualized in the renal parenchyma within 30 to 60 seconds. In patients with normal renal function, opacification of the calyces and pelves takes place within 1-3 minutes, with an optimum contrast within 5-15 minutes.

Mechanism of Action · 1 item

Ioversol is a highly soluble non-ionic ionidated contrast agent. Intravascular injection of ioversol opacifies those vessels in the path of the flow of the contrast medium, allowing the radiographic visualization of the internal structures until significant hemodilution occurs. In imaging procedures, ioversol diffuses from the vascular to the extravascular space. In brains with an intact blood-brain barrier, this agent does not diffuse to the extravascular space. However, in patients with a disrupted blood-brain barrier, ioversol accumulates in the interstitial space of the disrupted region. As the product Optiray, ioversol enhances computed tomographic imaging through augmentation of radiographic efficiency with the degree of density enhancement directly related to the iodine content in an administered dose.

Biological Half-LifeThe elimination half-life was 1.5 hr in healthy volunteers (n=12) receiving 50 and 150 mL of ioversol 68%. In patients with renal dysfunction, the elimination half-life of ioversol is prolonged.
Metabolism/MetabolitesIoversol does not undergo significant metabolism, deiodination or biotransformation.
FDA Pharmacological Classification · 6 items

N3RIB7X24K

IOVERSOL

Established Pharmacologic Class [EPC] - Radiographic Contrast Agent

Mechanisms of Action [MoA] - X-Ray Contrast Activity

Ioversol is a Radiographic Contrast Agent. The mechanism of action of ioversol is as a X-Ray Contrast Activity.

IOVERSOL

MeSH Pharmacological ClassificationSubstances used to allow enhanced visualization of tissues.
Absorption, Distribution and Excretion · 4 items

Healthy volunteers that received 50 and 150 mL of ioversol, had a corresponding Cmax of 1.45 mg/mL and 2.36 mg/mL and a corresponding tmax of 2.0 min and 4.3 min. AUC was 1.74 mg⋅hr/mL in healthy volunteers that received 50 mL of ioversol, and 4.43 mg⋅hr/mL in those that received 150 mL. The pharmacokinetics of ioversol follow an open two compartment model with first-order elimination. Since ioversol is almost completely excreted by the kidney as a parent drug, patients with renal impairment are expected to have a lower elimination rate.

Following intravascular administration, ioversol is excreted mainly through the kidneys. Within the first 24 hours, more than 95% of the administered dose is excreted. Urine concentration peaks in the first 2 hours after ioversol is administered. Fecal elimination is negligible.

In adults, the volume of distribution of ioversol was 0.26 L/kg body weight, consistent with its extracellular space distribution.

In healthy volunteers that received 50 mL of ioversol, clearance was 156 mL/min, and in those receiving 150 mL of ioversol, clearance was 185 mL/min.

Uses & manufacturing

UsesUse (kg) in Switzerland (2009): >2500
Applications · 4 items

DescriptionLoversol is a kind of organioiodine compound that used as a contrast medium. It has high iodine content as well as several hydrophilic groups. It can be used for peripheral and coronary arteriography and left ventriculograpy, cardiovascular system angiography, cerebral angiography, venography, tomographic imaging of the head and body as well as intravenous excretory urography. It takes effects through opacifying those vessels in the path of the flow of the contrast medium, permitting radiographic visualization of the internal structure.

UsesLoversol is a radiopaque contrast agent. Ioversol contains iodine, a substance that absorbs x-rays. Contrast agents are used to allow blood vessels, organs, and other non-bony tissues to be seen more clearly on a CT scan or other radiologic (x-ray) examination.

UsesNonionic, low osmolality, radiographic contrast agent. Diagnostic aid (radiopaque medium).

General DescriptionIoversol is a low-osmolar, nonionicmonomer with 47% bound iodine content. It is indicated forangiography, excretory urography, ventriculography, andvarious CT procedures.

Upstream & downstream products

Upstream raw materials

5-[2-chloro-N-(2-hydroxyethyl)acetamido]-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide5-Amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamideN-DesMethyl IoMeprol5 - chloro-acetamido-N, N - bis (2,3 - dihydroxypropyl) -2,4,6 - triiodo-1 ,3. Phthalimido5-[[2-(Acetyloxy)acetyl]amino]-2,4,6-triiodo-1,3-benzenedicarbonyl Dichloride

Additional notes

DefinitionLoversol is classified as an organoiodine compound and is used as a contrast dye in diagnostic procedures. It contains high levels of iodine in addition to various hydrophilic groups.

Related reactions

3 records
New reaction record
HRID 265750 reaction equation
HRID 265750As product
HRID 1358849 reaction equation
HRID 1358849As product
HRID 2395870 reaction equation
HRID 2395870As product

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes